About
Merck KGaA partners with Valo Health in a $3 billion AI-driven initiative to identify disease patterns for Parkinson's. This strategic move aims to rebuild Merck's pharmaceutical pipeline amidst competitive pressures and pipeline setbacks. The partnership includes upfront payments, milestones, royalties, and R&D funding. CEO Belen Garijo's upcoming departure and recent acquisitions highlight Merck's focus on strengthening its neurology pipeline.
VIPC signs MoU with AstraZeneca, Eli Lilly, Merck
VIPC signed an MOU with AstraZeneca, Eli Lilly, and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing. This $120 million investment aims to train the future workforce in Virginia's life sciences ecosystem, creating thousands of jobs. The center will collaborate with Virginia's universities and community colleges to offer industry-aligned training and education. This partnership enhances Virginia's innovation ecosystem and economic growth through collaboration and innovation.
Evercore ISI has reduced its price target for BellRing Brands from $40.00 to $35.00, maintaining an "outperform" rating. Other analysts have also adjusted their targets, with JPMorgan lowering to $45.00 and Barclays setting a $32.00 objective. The stock has a consensus "Moderate Buy" rating with a target of $47.06. BellRing Brands announced a $400 million stock repurchase plan, indicating potential undervaluation. The stock recently traded up 7.2% to $28.15.
Shares of protein-based food and beverages co BellRing Brandsrise nearly 4.5% to about $30.6 premarketBRBR to repurchase up to $600 million of shares over next two years, effective November 19As of November 19, co had repurchased ~$123 million under its previous $400 million buyback program started on September 2 and canceled on November 19Thirteen of 17 brokerages rate stock “buy” or higher and four “hold”; their median PT is $39 - data compiled by LSEGAs of last close, shares down 61.2% YTD
